NCT07613411尚未招募1 期
A Clinical Study to Evaluate the Safety and Efficacy of KSVCBD Injection in Patients With Autoimmune Diseases
Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, early exploratory clinical study is designed to evaluate the safety and preliminary efficacy of KSVCBD injection in patients with Autoimmune Diseases.
详细描述
KSVCBD-R102 is an open-label study in subjects with autoimmune diseases and will be conducted in two stages: dose escalation (Stage A) and dose expansion (Stage B). In Stage A, a total of three dose levels explored. At the recommended dose established during the dose-escalation phase, subjects will be enrolled in a dose-expansion study to further evaluate the safety and preliminary efficacy of KSVCBD injection in subjects with autoimmune diseases. The dose-expansion study will explore two separate cohorts, each enrolling subject with an indication for which preliminary efficacy data have been obtained during the dose-escalation phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-65 years (inclusive), any gender.
- •Subjects diagnosed with the following autoimmune disease: moderate/severe refractory Systemic Lupus Erythematosus, elapsed/refractory Systemic Sclerosis, relapsed/refractory ANCA-Associated Vasculitis, refractory Idiopathic Inflammatory Myopathy, active Sjögren's Syndrome, chronic/refractory Immune Thrombocytopenia, refractory Antiphospholipid Syndrome, relapsed/refractory pemphigus, relapsed/refractory IgG4-Related Disease.
- •Having adequate organ function as required by the protocol.:
- •Voluntarily adhere to the contraception requirements as specified in the protocol.
- •Willing to comply with all study procedures and voluntarily participate in this study and sign the informed consent form (ICF).
排除标准
- •Previous or current active malignancy, including patients with cancer-associated polymyositis/dermatomyositis. Exceptions are cured or relapse-free for at least 3 years: cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer, locally advanced prostate cancer after radical treatment, or ductal carcinoma in situ after radical surgery.
- •Severe pulmonary disease within the past 1 year, such as moderate/severe pulmonary arterial hypertension (pulmonary artery systolic pressure >50 mmHg on echocardiography), requirement for oxygen therapy via reservoir mask or non-invasive/invasive ventilator support at screening.
- •Use of any of the protocol specified drugs or treatments within the specified timeframes.
- •History or current symptoms of severe central nervous system (CNS) disease within the past 6 months.
- •Known severe allergy to the study drug or any of its components.
- •Presence of uncontrolled fungal, bacterial, or viral infection, or other infections considered by the investigator to make the subject unsuitable for participation.
- •History of major organ transplant or hematopoietic stem cell/bone marrow transplantation.
- •History of other autoimmune diseases requiring systemic treatment, other than the target indication.
- •History of non-IIM conditions such as drug induced myopathy, HIV associated myopathy, thyroid myopathy, or family history of myopathy.
- •Pregnant or breastfeeding women.
- •Use of any live vaccines within 6 weeks before enrollment.
- •Participation in another interventional clinical study and receipt of an active investigational drug within 3 months prior to signing the ICF, or intention to participate in another clinical trial or receive treatment for autoimmune diseases outside the protocol during the entire study period.
- •Psychiatric disorders with depression or suicidal tendencies.
- •Any other factors considered by the investigator to make the subject unsuitable for enrollment or to affect the subject's participation or completion of the study.
研究者
Jian Zhu
Chief Physician and Professor
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMAMultiple MyelomaNCT07620275Chinese PLA General Hospital9
招募中
1 期
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMANCT07620314Chinese PLA General Hospital9
招募中
1 期
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple SclerosisMultiple SclerosisNCT07303790Daishi Tian9
招募中
早期 1 期
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell NeoplasmsNCT07416682Affiliated Hospital to Academy of Military Medical Sciences20
招募中
2 期
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/LeukemiaNCT07321301Daihong Liu10